Viatris Just Snagged a Major FDA Approval
In early February, the U.S. Food and Drug Administration (FDA) gave the nod to Viatris' (NASDAQ: VTRS) Restasis, a generic version of AbbVie's (NYSE: ABBV) dry eye disease eyedrop treatment.
Since Viatris launched the drug in the U.S. immediately after the FDA approval, let's dig into what it could mean for patients and how much a boost the news could be for the pharma stock.
Image source: Getty Images.
Source Fool.com
